LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Bookmark and Share
Published: 25 Jun 2020
Views: 306
Rating:
Save
Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy

Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He outlines the background, design and results of this phase II randomised trial (LOW-PV), which is comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera.

Prof Barbui concludes that ropeginterferon is safe and effective in the haematocrit on target in low-risk patients with polycythemia vera.